Janssen receives EU approval for HIV drug Symtuza

Janssen has announced that its new HIV therapy Symtuza has been approved by the European Commission.

The once-daily darunavir-based single-tablet regimen has been ratified for the treatment of HIV-1 infections in adults and adolescents aged 12 years and older with body weight of at least 40 kg.

It has been developed to combine the proven efficacy and durability of darunavir, as well as its high genetic barrier to resistance, with the benefits of cobicistat, emtricitabine and tenofovir alafenamide, as well as the convenience of a single-tablet regimen.

Clinical trial data has shown that Symtuza offers an equivalent performance to the combined administration of the separate agents, with a low cumulative virologic rebound rate and a high virologic suppression rate.

Dr Lawrence Blatt, global therapeutic area head of Janssen's infectious disease therapeutics business, said: "Today's approval by the European Commission demonstrates our efforts to treat HIV more simply, helping all those living with HIV to achieve an undetectable viral load while enjoying an improved quality of life."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.